Recruiting soon

DC-CTLDC-CTL Cells for Solid Tumors Treatment

Study Aim

This study aims to assess the effectiveness of DC-CTL cells in extending the progression-free survival time for individuals with solid tumors.

What is being tested

Tumor polypeptide pool induced DC-CTL cell injection

Biological

Who is being recruted

Over 18 Years

+20 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Interventional

Study Start: March 2025

See protocol details

Summary

Principal SponsorZhengzhou Revo-Gene Technology Co., LTD

Study ContactHui Zhao, PhD

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: March 11, 2025

Actual date on which the first participant was enrolled.

This study aims to explore the safety and initial effectiveness of a treatment that combines DC-CTL cells with regular anti-tumor therapies for patients with solid tumors like colorectal cancer, esophageal cancer, lung cancer, liver cancer, and breast cancer. The goal is to find out how well this combination treatment works and whether it is safe for patients. Understanding these factors can help improve treatment options for people suffering from these types of cancers. Participants in the study receive DC-CTL cell injections on two consecutive days shortly after their regular cancer treatment. Before receiving a second round of DC-CTL cells, they get a small injection of DC cells under the skin. This process is repeated for about 4-6 cycles, depending on each patient's needs. The study monitors the safety of the treatment first, followed by its effectiveness during follow-up visits. If a participant's disease worsens, doctors assess whether they should continue in the study. Participants who start other treatments or choose to leave the study are monitored for survival outcomes.

Official TitleClinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors

NCT06524024

Principal SponsorZhengzhou Revo-Gene Technology Co., LTD

Study ContactHui Zhao, PhD

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

10 inclusion criteria required to participate

Age ≥18 years old, gender is not limited;

Patients clinically diagnosed with solid tumors such as colorectal cancer, esophageal cancer, lung cancer, liver cancer, breast cancer, etc., who need routine anti-tumor therapy;

KPS score ≥80 (Appendix 1), expected survival ≥3 months;

If imaging is available, the target lesion can be measured by conventional CT or MRI≥10 mm, and the short diameter of lymph node ≥15mm;

Show More Criteria

10 exclusion criteria prevent from participating

Pregnant or lactating women (women of childbearing age need to do pregnancy tests);

Had a serious, uncontrolled infectious disease (bacterial, viral, or fungal infection) within 4 weeks prior to enrollment;

have chronic active hepatitis, AIDS or syphilis;

have a serious autoimmune disease or immunodeficiency disease (such as systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis);

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

Biological: DC-CTL DC combined with CTL

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has no location dataSave this study to your profile to know when the location data is available.

Recruiting soonNo study centers